Active surveillance program for prostate cancer: An update of the Johns Hopkins experience

Journal of Clinical Oncology

Volumn 29, Issue 16, 2011, Pages 2185-2190

  Tosoian, Jeffrey J ^a   Trock, Bruce J ^a   Landis, Patricia ^a   Feng, Zhaoyong ^a   Epstein, Jonathan I ^a   Partin, Alan W ^a   Walsh, Patrick C ^a   Carter, H Ballentine ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER EPIDEMIOLOGY; CANCER MORTALITY; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; FOLLOW UP; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT SELECTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE BIOPSY; PROSTATE CANCER; SCORING SYSTEM; TUMOR BIOPSY;

AGED; AGED, 80 AND OVER; BIOPSY; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM STAGING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; WATCHFUL WAITING;

EID: 79957957477     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.32.8112     Document Type: Article

References (29)

1. Draisma G, Boer R, Otto SJ, et al: Lead times and overdetection due to prostate-specific antigen screening: Estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 95:868-878, 2003 (Pubitemid 36833878)
2. Schröder FH, Hugosson J, Roobol MJ, et al: Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 360:1320-1328, 2009
3. Hugosson J, Carlsson S, Aus G, et al: Mortality results from the Gö teborg randomised population-based prostate-cancer screening trial. Lancet Oncol 11:725-732, 2010
4. Welch HG, Black WC: Overdiagnosis in cancer. J Natl Cancer Inst 102:605-613, 2010
5. Cooperberg MR, Moul JW, Carroll PR: The changing face of prostate cancer. J Clin Oncol 23:8146-8151, 2005 (Pubitemid 46211547)
6. Holmberg L, Bill-Axelson A, Garmo H, et al: Prognostic markers under watchful waiting and radical prostatectomy. Hematol Oncol Clin North Am 20:845-855, 2006 (Pubitemid 44088597)
7. Carter HB, Kettermann A, Warlick C, et al: Expectant management of prostate cancer with curative intent: An update of the Johns Hopkins experience. J Urol 178:2359-2364, 2007; discussion 2364-2365
8. Khatami A, Ali K, Aus G, et al: PSA doubling time predicts the outcome after active surveillance in screening-detected prostate cancer: Results from the European randomized study of screening for prostate cancer, Sweden section. Int J Cancer 120:170-174, 2007 (Pubitemid 44901932)
9. Soloway MS, Soloway CT, Williams S, et al: Active surveillance; a reasonable management alternative for patients with prostate cancer: The Miami experience. BJU Int 101:165-169, 2008 (Pubitemid 350294039)
10. van As NJ, Norman AR, Thomas K, et al: Predicting the probability of deferred radical treatment for localised prostate cancer managed by active surveillance. Eur Urol 54:1297-1305, 2008
11. van den Bergh RC, Roemeling S, Roobol MJ, et al: Outcomes of men with screen-detected prostate cancer eligible for active surveillance who were managed expectantly. Eur Urol 55:1-8, 2009
12. Klotz L, Zhang L, Lam A, et al: Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 28:126-131, 2010
13. Harlan SR, Cooperberg MR, Elkin EP, et al: Time trends and characteristics of men choosing watchful waiting for initial treatment of localized prostate cancer: Results from CaPSURE. J Urol 170:1804-1807, 2003
14. Carter HB, Walsh PC, Landis P, et al: Expectant management of nonpalpable prostate cancer with curative intent: Preliminary results. J Urol 167:1231-1234, 2002 (Pubitemid 34132060)
15. Epstein JI, Walsh PC, Carmichael M, et al: Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 271:368-374, 1994 (Pubitemid 24037911)
16. Mohler J, Bahnson RR, Boston B, et al: NCCN clinical practice guidelines in oncology: Prostate cancer. J Natl Compr Canc Netw 8:162-200, 2010
17. Roach M 3rd, Hanks G, Thames H Jr, et al: Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 65:965-974, 2006
18. Chu KC, Tarone RE, Freeman HP: Trends in prostate cancer mortality among black men and white men in the United States. Cancer 97:1507-1516, 2003 (Pubitemid 36297781)
19. Choo R, Klotz L, Danjoux C, et al: Feasibility study: Watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression. J Urol 167:1664-1669, 2002 (Pubitemid 34240696)
20. Klotz L: Active surveillance for prostate cancer: A review. Curr Urol Rep 11:165-171, 2010
21. van den Bergh RC, Steyerberg EW, Khatami A, et al: Is delayed radical prostatectomy in men with low-risk screen-detected prostate cancer associated with a higher risk of unfavorable outcomes? Cancer 116:1281-1290, 2010
22. Eggener SE, Mueller A, Berglund RK, et al: A multi-institutional evaluation of active surveillance for low risk prostate cancer. J Urol 181:1635-1641, 2009
23. Dall'Era MA, Konety BR, Cowan JE, et al: Active surveillance for the management of prostate cancer in a contemporary cohort. Cancer 112:2664-2670, 2008 (Pubitemid 351969209)
24. van den Bergh RC, Vasarainen H, van der Poel HG, et al: Short-term outcomes of the prospective multicentre 'Prostate Cancer Research International: Active Surveillance' study. BJU Int 105:956-962, 2010
25. Duffield AS, Lee TK, Miyamoto H, et al: Radical prostatectomy findings in patients in whom active surveillance of prostate cancer fails. J Urol 182:2274-2278, 2009
26. Tseng KS, Landis P, Epstein JI, et al: Risk stratification of men choosing surveillance for low risk prostate cancer. J Urol 183:1779-1785, 2010
27. Ross AE, Loeb S, Landis P, et al: Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program. J Clin Oncol 28:2810-2816, 2010
28. Tosoian JJ, Loeb S, Kettermann A, et al: Accuracy of PCA3 measurement in predicting shortterm biopsy progression in an active surveillance program. J Urol 183:534-538, 2010
29. Fradet V, Kurhanewicz J, Cowan JE, et al: Prostate cancer managed with active surveillance: Role of anatomic MR imaging and MR spectroscopic imaging. Radiology 256:176-183, 2010